Overview
- Interim Heart-2 results reported this week from 35 adults show dose‑dependent LDL reductions with a mean 62% drop at the highest 1.0 mg/kg dose and evidence of durable effects in some participants for up to 18 months.
- VERVE-102 uses an in vivo adenine base editor delivered to the liver to introduce a stop mutation in the PCSK9 gene so the body should permanently make less PCSK9 protein and clear more LDL cholesterol.
- Early safety data recorded no treatment-related serious adverse events but did show mild-to-moderate infusion reactions, transient liver enzyme elevations, and one case of aspiration pneumonitis in a participant with prior GERD.
- Eli Lilly, which bought Verve last year, is advancing the program with plans for larger Phase 2 studies and has reported Fast Track status while regulators expect extensive long-term follow-up before wider use.
- If later trials confirm safety and durability, a one-time edit could replace chronic PCSK9 therapies and improve adherence, but unanswered questions remain about off-target effects, long-term risk, manufacturing scale and cost.